Allergy Diagnostic Testing: an Updated Practice Parameter

Total Page:16

File Type:pdf, Size:1020Kb

Allergy Diagnostic Testing: an Updated Practice Parameter ANNALS OF ALLERGY, ASTHMA, & IMMUNOLOGY March 2008; Volume 100, Number 3, Supplement 3 Allergy Diagnostic Testing: An Updated Practice Parameter Practice Parameter Allergy Diagnostic Testing: An Updated Practice Parameter I. Leonard Bernstein, MD; James T. Li, MD, PhD; David I. Bernstein, MD; Robert Hamilton, PhD, DABMLI; Sheldon L. Spector, MD; Ricardo Tan, MD; Scott Sicherer, MD; David B. K. Golden, MD; David A. Khan, MD; Richard A. Nicklas, MD; Jay M. Portnoy, MD; Joann Blessing-Moore, MD; Linda Cox, MD; David M. Lang, MD; John Oppenheimer, MD; Christopher C. Randolph, MD; Diane E. Schuller, MD; Stephen A. Tilles, MD; Dana V. Wallace, MD; Estelle Levetin, PhD; and Richard Weber, MD TABLE OF CONTENTS I. Preface .................................................................................... S2 II. Executive Summary ......................................................................... S3 III. Collation of Summary Statements .............................................................. S5 IV. Part 1 .................................................................................... S15 V. In Vivo Diagnostic Tests of Immediate Hypersensitivity Reactions .................................. S15 VI. Organ Challenge Tests ...................................................................... S29 VII. Tests to Distinguish Clinical Obstructive Diseases Resembling Asthma ............................... S33 VIII. In Vivo Diagnostic Tests of Cell-Mediated Immunity ............................................. S34 IX. In Vitro Diagnostic Tests of Immediate Hypersensitivity........................................... S43 X. In Vitro Diagnostic Tests of Cell-Mediated Immunity ............................................. S59 XI. Other Diagnostic Immunologic Tests........................................................... S64 XII. Unproven Tests ............................................................................ S65 XIII. Part 2 .................................................................................... S66 XIV. Allergens ................................................................................. S67 XV. Assessment of Inhalant Allergy ............................................................... S74 XVI. Assessment of Food Allergy................................................................. S102 XVII. Assessment of Stinging Insect Allergy ........................................................ S106 XVIII. Assessment of Drug Allergy................................................................. S109 XIX. Assessment of Allergic Contact Dermatitis ..................................................... S115 XX. Acknowledgments ......................................................................... S121 XXI. References ............................................................................... S122 The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology AAAAI or ACAAI interpretation of these practice parameters. Any (ACAAI) have jointly accepted responsibility for establishing the request for information about or an interpretation of these practice Allergy Diagnostic Testing: An Updated Practice Parameter. This is a parameters by the AAAAI or ACAAI should be directed to the complete and comprehensive document at the current time. The medical Executive Offices of the AAAAI, the ACAAI, and the Joint Council of environment is a changing environment and not all recommendations Allergy, Asthma and Immunology. These parameters are not designed will be appropriate for all patients. Because this document incorporated for use by pharmaceutical companies in drug promotion. the efforts of many participants, no single individual, including those Received for publication October 27, 2007; Accepted for publication who served on the Joint Task Force, is authorized to provide an official November 16, 2007. VOLUME 100, MARCH, 2008 S1 PREFACE anticipated to serve as a reference source for current utility The major emphasis of this updated version of Practice and validity of allergy diagnostic tests. Parameters for Allergy Diagnostic Testing is focused on how The organization of Practice Parameters on Allergy Diag- technological refinements and their validations during the nostic Tests is similar to previous Joint Task Force parame- past decade are being incorporated into the diagnostic arma- ters except that a single algorithm with annotations was not mentarium of allergists/clinical immunologists and how their appropriate to the mission of the parameter. The broad range optimal use enables confirmation of human clinical sensitiv- of diagnostic techniques for varying purposes could not pos- ity. The term allergy in this Practice Parameter denotes major sibly be stratified into a uniform paradigm encompassing categories of human hypersensitivity. Pertinent clinical im- diverse clinical sensitivity disorders that require objective munologic techniques are oriented to this category of adap- confirmatory tests. An Executive Summary is followed by a tive immunity but not to infection, cancer, or transplantation collation of Summary Statements, which also precede refer- immunology. enced narrative discussions on each subject. The Practice The impetus for Practice Parameters for Allergy Diagnos- Parameter is divided into 2 parts: part 1 is a detailed descrip- tic Testing originally stemmed from a consensus conference tion of diagnostic modalities currently available to allergists/ sponsored by the National Institute of Allergy and Infectious clinical immunologists. It encompasses both IgE and cell- Diseases and published as a supplement to the Journal of mediated in vivo (skin and patch) and in vitro tests for a wide Allergy and Clinical Immunology in September 1988. One of spectrum of inhalant, food, and contactant allergens. Organ the major conclusions of that workshop was that periodic challenge tests are discussed in greater detail in this revised reassessment of diagnostic techniques should be mandatory, Practice Parameter because controlled challenges or super- and in keeping with that recommendation, the 1995 Practice vised exposure ultimately serve as the appropriate gold stan- Parameters for Allergy Diagnostic Tests further reviewed and dard for assessing whether clinical sensitivity is present. considered new developments up to that time. In the 13-year Consonant with their recent emergence as diagnostic ad- juncts, the section concerning current status of cytokines and interval since that publication, there has been an exponential chemokines has been expanded. A new section on “Other progression of basic and translational immunologic research, Immunologic Tests” has been added in recognition that many some of which produced novel and practical diagnostic pos- allergists/clinical immunologists have considerable interests sibilities. Obviously, these advancements necessitated an and expertise in a variety of laboratory immunologic tech- overhaul of the 1995 Allergy Diagnostic Parameter commen- niques commonly used to corroborate the diagnosis of non- surate with the extensive database currently available. The IgE, non–cell-mediated clinical immunologic diseases. A ultimate goals were to formulate recommendations based on discussion about unproven techniques is relevant because evidence-based literature and to achieve balanced use of these methods still have advocates who promote them to classic and new diagnostic methods. patients desperately seeking alternative approaches for their The working draft of the Parameter on Allergy Diagnostic particular problems. Tests update was based on an outline jointly conceived by Part 2 considers optimal utilization and integration of ev- James T. Li and I. Leonard Bernstein and realized by a work idence-based diagnostic methods for various clinical situa- group (Robert Hamilton, Sheldon Spector, Ricardo Tan, tions, which include inhalant, food, insect venom, drug and David I. Bernstein, Scott Sicherer, David B. K. Golden, and contact sensitivities. Practice parameters of diagnosis and David Khan) chaired by I. Leonard Bernstein. As with pre- management for each of these clinical entities have been vious parameters, the draft was based on a review of the previously published with algorithms tailored to fit the spe- medical literature using a variety of search engines, such as cific clinical situation. Many of the diagnostic recommenda- PubMed. Published clinical and basic studies were rated by tions of part 2 were extracted or in some cases quoted categories of evidence and used to establish the strength of verbatim from each of these published guidelines. recommendations (Table 1). The initial draft was then re- The Joint Task Force acknowledges that rapid advance- viewed by all members of the Joint Task Force and subse- ments in diagnostic technology could render specific past and quently by the American Academy of Allergy, Asthma and current recommendations obsolete at any time and that at- Immunology (AAAAI), the American College of Allergy, tempts to revise will have to be undertaken at appropriate Asthma and Immunology (ACAAI), and the Joint Council of intervals. Nevertheless, whatever the update interim period Allergy, Asthma and Immunology and a number of experts may be, the allergy/clinical immunology community should on in vivo and in vitro diagnostic immunology selected by the be prepared to accept novel new diagnostic techniques, pro- supporting organizations. Comments were also solicited from
Recommended publications
  • Gene Expression Polarization
    Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression This information is current as of September 27, 2021. Fernando O. Martinez, Siamon Gordon, Massimo Locati and Alberto Mantovani J Immunol 2006; 177:7303-7311; ; doi: 10.4049/jimmunol.177.10.7303 http://www.jimmunol.org/content/177/10/7303 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2006/11/03/177.10.7303.DC1 Material http://www.jimmunol.org/ References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/177/10/7303.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 Fernando O.
    [Show full text]
  • Cellular and Plasma Proteomic Determinants of COVID-19 and Non-COVID-19 Pulmonary Diseases Relative to Healthy Aging
    RESOURCE https://doi.org/10.1038/s43587-021-00067-x Cellular and plasma proteomic determinants of COVID-19 and non-COVID-19 pulmonary diseases relative to healthy aging Laura Arthur1,8, Ekaterina Esaulova 1,8, Denis A. Mogilenko 1, Petr Tsurinov1,2, Samantha Burdess1, Anwesha Laha1, Rachel Presti 3, Brian Goetz4, Mark A. Watson1, Charles W. Goss5, Christina A. Gurnett6, Philip A. Mudd 7, Courtney Beers4, Jane A. O’Halloran3 and Maxim N. Artyomov1 ✉ We examine the cellular and soluble determinants of coronavirus disease 2019 (COVID-19) relative to aging by performing mass cytometry in parallel with clinical blood testing and plasma proteomic profiling of ~4,700 proteins from 71 individuals with pul- monary disease and 148 healthy donors (25–80 years old). Distinct cell populations were associated with age (GZMK+CD8+ T cells and CD25low CD4+ T cells) and with COVID-19 (TBET−EOMES− CD4+ T cells, HLA-DR+CD38+ CD8+ T cells and CD27+CD38+ B cells). A unique population of TBET+EOMES+ CD4+ T cells was associated with individuals with COVID-19 who experienced moderate, rather than severe or lethal, disease. Disease severity correlated with blood creatinine and urea nitrogen levels. Proteomics revealed a major impact of age on the disease-associated plasma signatures and highlighted the divergent contri- bution of hepatocyte and muscle secretomes to COVID-19 plasma proteins. Aging plasma was enriched in matrisome proteins and heart/aorta smooth muscle cell-specific proteins. These findings reveal age-specific and disease-specific changes associ- ated with COVID-19, and potential soluble mediators of the physiological impact of COVID-19.
    [Show full text]
  • Anti-OX40 Antibody Directly Enhances the Function of Tumor-Reactive CD8+ T Cells
    Author Manuscript Published OnlineFirst on August 1, 2019; DOI: 10.1158/1078-0432.CCR-19-1259 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma Weiyi Peng1,5*, Leila J. Williams1, Chunyu Xu1,5, Brenda Melendez1, Jodi A. McKenzie1,6, Yuan Chen1, Heather Jackson2, Kui S. Voo3, Rina M. Mbofung1,7,, Sara E. Leahey1, Jian Wang4, Greg Lizee1, Hussein A. Tawbi1, Michael A. Davies1, Axel Hoos2, James Smothers2, Roopa Srinivasan2, Elaine Paul2, Niranjan Yanamandra2* and Patrick Hwu1* 1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 2Oncology R&D, Immuno-Oncology and Combinations RU, GlaxoSmithKline, 1250 S. Collegeville Rd, Collegeville, PA 19426, United States 3Oncology Research for Biologics and Immunotherapy Translation Platform, The University of Texas MD Anderson Cancer Center, Houston, TX. 4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. 5Present address: Department of Biology and Biochemistry, University of Houston, Houston, TX. 6Present address: Eisai Inc., Woodcliff Lake, NJ. 7Present address: Merck Research Laboratories, Palo Alto, CA. Running Title: OX40 agonist-based cancer immunotherapy Keywords: OX40, PI3K, cancer immunotherapy Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 1, 2019; DOI: 10.1158/1078-0432.CCR-19-1259 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 2 *Corresponding Authors: Patrick Hwu, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
    [Show full text]
  • Aeroallergen-Induced Th2 Inflammation Endogenous And
    Endogenous and Exogenous IL-6 Inhibit Aeroallergen-Induced Th2 Inflammation Jingming Wang, Robert J. Homer, Qingsheng Chen and Jack A. Elias This information is current as of September 26, 2021. J Immunol 2000; 165:4051-4061; ; doi: 10.4049/jimmunol.165.7.4051 http://www.jimmunol.org/content/165/7/4051 Downloaded from References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/165/7/4051.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 26, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Endogenous and Exogenous IL-6 Inhibit Aeroallergen-Induced Th2 Inflammation1 Jingming Wang,* Robert J. Homer,† Qingsheng Chen,* and Jack A. Elias2* Chronic Th2-dominated inflammation and exaggerated IL-6 production are characteristic features of the asthmatic airway. To understand the processes that are responsible for the chronicity of this response and the role(s) of IL-6 in the regulation of airway Th2 inflammation, we compared the responses induced by OVA in sensitized wild-type mice, IL-6 deficient (؊/؊) mice, and transgenic mice in which IL-6 was overexpressed in the airway (CC10-IL-6 mice).
    [Show full text]
  • Food Allergy Outline
    Allergy Evaluation-What it all Means & Role of Allergist Sai R. Nimmagadda, M.D.. Associated Allergists and Asthma Specialists Ltd. Clinical Assistant Professor Of Pediatrics Northwestern University Chicago, Illinois Objectives of Presentation • Discuss the different options for allergy evaluation. – Skin tests – Immunocap Testing • Understand the results of Allergy testing in various allergic diseases. • Briefly Understand what an Allergist Does Common Allergic Diseases Seen in the Primary Care Office • Atopic Dermatitis/Eczema • Food Allergy • Allergic Rhinitis • Allergic Asthma • Allergic GI Diseases Factors that Influence Allergies Development and Expression Host Factors Environmental Factors . Genetic Indoor allergens - Atopy Outdoor allergens - Airway hyper Occupational sensitizers responsiveness Tobacco smoke . Gender Air Pollution . Obesity Respiratory Infections Diet © Global Initiative for Asthma Why Perform Allergy Testing? – Confirm Allergens and answer specific questions. • Am I allergic to my dog? • Do I have a milk allergy? • Have I outgrown my allergy? • Do I need medications? • Am I penicillin allergic? • Do I have a bee sting allergy Tests Performed in the Diagnostic Allergy Laboratory • Allergen-specific IgE (over 200 allergen extracts) – Pollen (weeds, grasses, trees), – Epidermal, dust mites, molds, – Foods, – Venoms, – Drugs, – Occupational allergens (e.g., natural rubber latex) • Total Serum IgE (anti-IgE; ABPA) • Multi-allergen screen for IgE antibody Diagnostic Allergy Testing Serological Confirmation of Sensitization History of RAST Testing • RAST (radioallergosorbent test) invented and marketed in 1974 • The suspected allergen is bound to an insoluble material and the patient's serum is added • If the serum contains antibodies to the allergen, those antibodies will bind to the allergen • Radiolabeled anti-human IgE antibody is added where it binds to those IgE antibodies already bound to the insoluble material • The unbound anti-human IgE antibodies are washed away.
    [Show full text]
  • Allergen Regulations 105 Cmr 590.000
    ALLERGEN REGULATIONS 105 CMR 590.000: STATE SANITARY CODE CHAPTER X – MINIMUM SANITATION STANDARDS FOR FOOD ESTABLISHMENTS (1) ADD new definition in 105 CMR 590.002(B): Major Food Allergen means: (1) Milk, eggs, fish (such as bass, flounder, or cod), crustaceans (such as crab, lobster, or shrimp), tree nuts (such as almonds, pecans, or walnuts), wheat, peanuts, and soybeans; and (2) A FOOD ingredient that contains protein derived from a FOOD named in subsection (1). "Major food allergen" does not include: (a) Any highly refined oil derived from a FOOD specified in subsection (1) or any ingredient derived from such highly refined oil; or (b) Any ingredient that is exempt under the petition or notification process specified in the federal Food Allergen Labeling and Consumer Protection Act of 2004 (Public Law 108-282). (2) Amend the definitions of “menu” and “menu board” in 590.002(B) as follows: Menu means a printed list or pictorial display of a food item or items and their price(s) that are available for sale from a food establishment, and includes menus distributed or provided outside of the establishment. Menu Board means any list or pictorial display of a food item or items and their price(s) posted within or outside a food establishment. (3) Amend as follows 105 CMR 590.003(B) (Management and Personnel – federal 1999 Food Code Chapter 2) (B) FC 2-102.11 Demonstration … The areas of knowledge include: . (17) No later than February 1, 2011: (a) Describing FOODS identified as MAJOR FOOD ALLERGENS and describing the symptoms that MAJOR FOOD ALLERGENS could cause in a sensitive individual who has an allergic reaction; and (b) Ensuring that employees are properly trained in food allergy awareness as it relates to their assigned duties.
    [Show full text]
  • Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3
    RX Zhang, et al ORIGINAL ARTICLE Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3 1 Department of Otolaryngology, Huadong Hospital, Fudan University, Shanghai, China 2 Department of Otolaryngology , Jinan General Hospital of PLA, Shandong, China 3 Department of Otolaryngology, Changhai Hospital, Second Military Medical University, Shanghai, China ■ Abstract Objective: To analyze the roles of chemokines and their receptors in the pathogenesis of allergic rhinitis by observing the complementary DNA (cDNA) expression of the chemokines and their receptors in the nasal mucosa of patients with and without allergic rhinitis, using gene chips. Methods: The total RNAs were isolated from the nasal mucosa of 20 allergic rhinitis patients and purifi ed to messenger RNAs, and then reversely transcribed to cDNAs and incorporated with samples of fl uorescence-labeled with Cy5-dUPT (rhinitis patient samples) or Cy3- dUTP (control samples of nonallergic nasal mucosa). Thirty-nine cDNAs of chemokines and their receptors were latticed into expression profi le chips, which were hybridized with probes and then scanned with the computer to study gene expression according to the different fl uorescence intensities. Results: The cDNAs of the following chemokines were upregulated: CCL1, CCL2, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL17, CCL18, CCL19, CCL24, and CX3CL1 in most of the allergic rhinitis sample chips. CCR2, CCR3, CCR4, CCR5, CCR8 and CX3CR1 were the highly expressed receptor genes. Low expression of CXCL4 was found in these tissues. Conclusion: The T helper cell (TH) immune system is not well regulated in allergic rhinitis.
    [Show full text]
  • Anti-CCL13 / MCP4 Antibody (Biotin) (ARG65993)
    Product datasheet [email protected] ARG65993 Package: 50 μg anti-CCL13 / MCP4 antibody (Biotin) Store at: 4°C Summary Product Description Biotin-conjugated Goat Polyclonal antibody recognizes CCL13 / MCP4 Tested Reactivity Hu Tested Application ELISA, WB Host Goat Clonality Polyclonal Isotype IgG Target Name CCL13 / MCP4 Antigen Species Human Immunogen E. coli derived recombinant Human CCL13 / MCP4. (QPDALNVPST CCFTFSSKKI SLQRLKSYVI TTSRCPQKAV IFRTKLGKEI CADPKEKWVQ NYMKHLGRKA HTLKT) Conjugation Biotin Alternate Names SCYA13; C-C motif chemokine 13; Monocyte chemotactic protein 4; Small-inducible cytokine A13; CKb10; SCYL1; Monocyte chemoattractant protein 4; MCP-4; NCC-1; NCC1; CK-beta-10 Application Instructions Application table Application Dilution ELISA Direct: 0.25 - 1.0 µg/ml Sandwich: 0.25 - 1.0 µg/ml with ARG65992 as a capture antibody WB 0.1 - 0.2 µg/ml Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 11 kDa Properties Form Liquid Purification Purified by affinity chromatography. Buffer PBS (pH 7.2) Concentration 1 mg/ml Storage instruction Aliquot and store in the dark at 2-8°C. Keep protected from prolonged exposure to light. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Database links GeneID: 6357 Human Swiss-port # Q99616 Human Gene Symbol CCL13 Gene Full Name chemokine (C-C motif) ligand 13 Background This antimicrobial gene is one of several Cys-Cys (CC) cytokine genes clustered on the q-arm of chromosome 17.
    [Show full text]
  • Approaches for Assessing Health Risks from Complex Mixtures in Indoor Air: a Panel Overview by Carol J
    Environmental Health Perspectives Vol. 95, pp. 135-143, 1991 Approaches for Assessing Health Risks from Complex Mixtures in Indoor Air: A Panel Overview by Carol J. Henry,* Lawrence Fishbein,* William J. Meggs,t Nicholas A. Ashford,' Paul A. Schulte,§ Henry Anderson,/' J. Scott Osborne,' and Daniel W. Sepkovictt Critical to a more definitive human health assessment ofthe potential health risks from exposure to complex mixtures in indoor air is the need for a more definitive clinical measure and etiology ofthe helath effects ofcomplex mixtures. This panel overview highlights six ofthe eight presentations ofthe conference panel discussion and features a number ofthe major topical areas of indoor air concern. W. G. Meggs assessed clinical research priorities with primary focus on the role ofvolatile organic chemicals in human health, recognizing the areas where definitive data are lacking. By recogniz- ing many types ofchemical sensitivity, it may be possible to design studies that can illuminate the mechanisms by which chemical exposure may cause disease. The critically important topic of multiple chemical sensitivity was discussed by N. A. Ashford, who identified four high risk groups and defined the demographics ofthese groups. P. A. Schulte address- ed the issue ofbiological markers ofsusceptibility with specific considerations ofboth methodologia and societal aspects that may be operative in the ability to detect innate or inborne differences between individuals and populations. Three case studies were reviewed. H. Anderson discussed the past and present priorities from a public health perspective, focusing on those issues dealing with exposures to environmental tobacco smoke and formaldehyde off-gassing from materials used in mobile homeconstruction.
    [Show full text]
  • Aeroallergen Sensitization and Allergic Disease Phenotypes in Asia
    REVIEW ARTICLE Asian Pacific Journal of Allergy and Immunology Aeroallergen sensitization and allergic disease phenotypes in Asia Elizabeth Huiwen Tham,1,2 Alison Joanne Lee,1,2 Hugo Van Bever1,2 Abstract Allergic diseases are on the rise in Asia. Aeroallergen exposure is a strong risk factor for sensitization, development and severity of atopic diseases, especially in the Asian paediatric population. Geographical and seasonal variations in aeroallergen sensitization are seen even within Asian countries and changes in aeroallergen sensitization patterns have been observed over time. Some possible reasons include climate change as well as rapid urbanization and improved sanitation which follow socioeconomic development. House dust mite allergy is present in up to 90% of Asian atopic patients, far exceeding that which is seen in Western populations which report prevalences of only 50% to 70%. Pollen and animal dander affect less than 10% of Asian patients as compared to 40-70% of individuals with asthma and allergic rhinitis living in the West, a burden almost equivalent to the dust mite burden in those regions. There is thus a pressing need for preventive measures to reduce dust mite sensitization in Asian children today. Keywords: Aeroallergen, Asia, allergy, house dust mites, sensitization From: Corresponding author: 1 Department of Paediatrics, Yong Loo Lin School of Medicine, National Elizabeth Huiwen Tham University of Singapore Department of Paediatrics, Yong Loo Lin School of Medicine, National 2 Khoo Teck Puat-National University
    [Show full text]
  • Differential Expression of Interferon-Γ and Chemokine Genes
    Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Owens et al. Owens et al. Journal of Neuroinflammation 2013, 10:56 http://www.jneuroinflammation.com/content/10/1/56 Owens et al. Journal of Neuroinflammation 2013, 10:56 JOURNAL OF http://www.jneuroinflammation.com/content/10/1/56 NEUROINFLAMMATION RESEARCH Open Access Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Geoffrey C Owens1,7*, My N Huynh1, Julia W Chang1, David L McArthur1, Michelle J Hickey2, Harry V Vinters2,3, Gary W Mathern1,4,5,6† and Carol A Kruse1,6† Abstract Background: Rasmussen encephalitis (RE) is a rare complex inflammatory disease, primarily seen in young children, that is characterized by severe partial seizures and brain atrophy. Surgery is currently the only effective treatment option. To identify genes specifically associated with the immunopathology in RE, RNA transcripts of genes involved in inflammation and autoimmunity were measured in brain tissue from RE surgeries and compared with those in surgical specimens of cortical dysplasia (CD), a major cause of intractable pediatric epilepsy. Methods: Quantitative polymerase chain reactions measured the relative expression of 84 genes related to inflammation and autoimmunity in 12 RE specimens and in the reference group of 12 CD surgical specimens. Data were analyzed by consensus clustering using the entire dataset, and by pairwise comparison of gene expression levels between the RE and CD cohorts using the Harrell-Davis distribution-free quantile estimator method.
    [Show full text]
  • Ehrlichiosis and Anaplasmosis Are Tick-Borne Diseases Caused by Obligate Anaplasmosis: Intracellular Bacteria in the Genera Ehrlichia and Anaplasma
    Ehrlichiosis and Importance Ehrlichiosis and anaplasmosis are tick-borne diseases caused by obligate Anaplasmosis: intracellular bacteria in the genera Ehrlichia and Anaplasma. These organisms are widespread in nature; the reservoir hosts include numerous wild animals, as well as Zoonotic Species some domesticated species. For many years, Ehrlichia and Anaplasma species have been known to cause illness in pets and livestock. The consequences of exposure vary Canine Monocytic Ehrlichiosis, from asymptomatic infections to severe, potentially fatal illness. Some organisms Canine Hemorrhagic Fever, have also been recognized as human pathogens since the 1980s and 1990s. Tropical Canine Pancytopenia, Etiology Tracker Dog Disease, Ehrlichiosis and anaplasmosis are caused by members of the genera Ehrlichia Canine Tick Typhus, and Anaplasma, respectively. Both genera contain small, pleomorphic, Gram negative, Nairobi Bleeding Disorder, obligate intracellular organisms, and belong to the family Anaplasmataceae, order Canine Granulocytic Ehrlichiosis, Rickettsiales. They are classified as α-proteobacteria. A number of Ehrlichia and Canine Granulocytic Anaplasmosis, Anaplasma species affect animals. A limited number of these organisms have also Equine Granulocytic Ehrlichiosis, been identified in people. Equine Granulocytic Anaplasmosis, Recent changes in taxonomy can make the nomenclature of the Anaplasmataceae Tick-borne Fever, and their diseases somewhat confusing. At one time, ehrlichiosis was a group of Pasture Fever, diseases caused by organisms that mostly replicated in membrane-bound cytoplasmic Human Monocytic Ehrlichiosis, vacuoles of leukocytes, and belonged to the genus Ehrlichia, tribe Ehrlichieae and Human Granulocytic Anaplasmosis, family Rickettsiaceae. The names of the diseases were often based on the host Human Granulocytic Ehrlichiosis, species, together with type of leukocyte most often infected.
    [Show full text]